| Resveratrol supplementation improves functional performance in knee osteoarthritis by upregulating sirtuin 1: a randomized study 2025 · intervention group · Adults aged 63–73 with knee osteoarthritis | 500 mg | 12 weeks | 67 |
| Resveratrol treatment increases sirtuin 1 levels and alleviates frailty phenotype in knee osteoarthritis patients: a randomised placebo-controlled clinical trial 2025 · resveratrol group · Patients aged 63–75 years with knee osteoarthritis | 500 mg | 16 weeks | 59 |
| Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study 2018 · resveratrol group · Men and women aged 45–75 with clinically diagnosed knee osteoarthritis, radiographic grade 1–3, and baseline WOMAC pain assessment above 50/96 | 500 mg | 90 days | 55 |
| Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam 2021 · Mlx + Res · Adults aged 45 years or older with mild-to-moderate painful knee osteoarthritis | 500 mg | 90 days | 50 |
| Resveratrol decreases local inflammatory markers and systemic endotoxin in patients with aggressive periodontitis 2022 · high-dose group (HRV) · Adults over 18 with periodontitis; mean age about 25 years; men and women | 500 mg | 8 weeks | 40 |
| Sirtuin 1 and Vascular Function in Healthy Women and Men: A Randomized Clinical Trial Comparing the Effects of Energy Restriction and Resveratrol 2023 · resveratrol group · Healthy men aged 55–65 and healthy postmenopausal women, without chronic non-communicable disease or previous cardiovascular disease | 500 mg | 30 days | 24 |
| Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial 2021 · EX + 500 mg/day resveratrol (EX500) · Adults aged 65 years or older with functional limitations and low physical activity | 500 mg | 12 weeks | 20 |
| Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial 2025 · RSV · smoking patients with periodontitis | 500 mg | 180 days | 19 |
| Resveratrol Supplementation and Oxidative/Anti-Oxidative Status in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study 2016 · resveratrol group · Patients with active mild to moderate ulcerative colitis | 500 mg | 6 weeks | — |
| Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial 2021 · resveratrol · Patients with ADHD; age and sex not specified | 500 mg | 8 weeks | — |
| Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study 2018 · RSV-treated group · Adults with rheumatoid arthritis; 68 women and 32 men enrolled across the study, with 50 assigned to this arm | 1 g | 90 days | 50 |
| Resveratrol decreases local inflammatory markers and systemic endotoxin in patients with aggressive periodontitis 2022 · middle-dose group (MRV) · Adults over 18 with periodontitis; mean age about 26 years; men and women | 250 mg | 8 weeks | 40 |
| Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS 2021 · resveratrol group · Women aged 18–40 years with PCOS diagnosed by the Rotterdam criteria | 1 g | 90 days | 39 |
| Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus 2016 · 300 mg resveratrol · Adults aged 49–78 years with type 2 diabetes mellitus, dementia-free and non-insulin dependent | 300 mg | 1 day | 36 |
| Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus 2016 · 300 mg resveratrol · Adults aged 40–80 years with type 2 diabetes mellitus | 300 mg | 1 day | 36 |
| Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial 2018 · resveratrol group · Males and females aged 20 to 60 years with nonalcoholic fatty liver disease (NAFLD) and BMI 25 to 35 kg/m² | 600 mg | 12 weeks | 30 |
| Effect of Resveratrol on Endothelial Function in Patients with CKD and Diabetes: A Randomized Controlled Trial 2024 · resveratrol supplementation · Adults aged 68±7 years, 84% men, with stage 3 CKD and diabetes | 400 mg | 6 weeks | 28 |
| Beneficial effects of acute trans-resveratrol supplementation in treated hypertensive patients with endothelial dysfunction 2018 · trans-resveratrol · Men and women aged 45–65 with treated hypertension and baseline endothelial dysfunction | 300 mg | 1 day | 24 |
| Recovery Of Bone And Muscle Mass In Patients With Chronic Kidney Disease And Iron Overload On Hemodialysis And Taking Combined Supplementation With Curcumin And Resveratrol 2019 · Group A (Resveratrol + Curcumin) · Adults with chronic kidney disease and iron overload undergoing hemodialysis; age and sex not restricted | 500 mg | 12 weeks | 20 |
| Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial 2021 · EX + 1,000 mg/day resveratrol (EX1000) · Adults aged 65 years or older with functional limitations and low physical activity | 1 g | 12 weeks | 20 |
| A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea) 2021 · higher-dose resveratrol · Male veterans aged 46–57 with Gulf War Illness | 600 mg | 30 days | 9 |
| Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial 2017 · resveratrol · Patients diagnosed with acute Takayasu arteritis | 250 mg | 90 days | — |
| Effects of 90 Days of Resveratrol Supplementation on Cognitive Function in Elders: A Pilot Study 2018 · 300 mg/day resveratrol · Sedentary, overweight adults aged 65–93 years | 300 mg | 90 days | — |
| Effects of 90 Days of Resveratrol Supplementation on Cognitive Function in Elders: A Pilot Study 2018 · 1000 mg/day resveratrol · Sedentary, overweight adults aged 65–93 years | 1 g | 90 days | — |
| Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 2018 · Resv500 arm · Adults aged 40 years or older with diagnosed type 2 diabetes; median age 66 years, predominantly men, all women postmenopausal | 500 mg | 26 weeks | 65 |
| Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study 2021 · resveratrol · Postmenopausal women aged 45–85 years | 150 mg | 1 year | 125 |
| δ-Tocotrienol in Combination with Resveratrol Improves the Cardiometabolic Risk Factors and Biomarkers in Patients with Metabolic Syndrome: A Randomized Controlled Trial 2023 · TRM · Adults aged 18–60 years with metabolic syndrome | 300 mg | 24 weeks | 41 |
| Resveratrol decreases local inflammatory markers and systemic endotoxin in patients with aggressive periodontitis 2022 · low-dose group (LRV) · Adults over 18 with periodontitis; mean age about 27 years; men and women | 125 mg | 8 weeks | 40 |
| Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus 2016 · 75 mg resveratrol · Adults aged 49–78 years with type 2 diabetes mellitus, dementia-free and non-insulin dependent | 75 mg | 1 day | 36 |
| Low dose resveratrol improves cerebrovascular function in type 2 diabetes mellitus 2016 · 150 mg resveratrol · Adults aged 49–78 years with type 2 diabetes mellitus, dementia-free and non-insulin dependent | 150 mg | 1 day | 36 |
| Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus 2016 · 75 mg resveratrol · Adults aged 40–80 years with type 2 diabetes mellitus | 75 mg | 1 day | 36 |
| Acute Resveratrol Consumption Improves Neurovascular Coupling Capacity in Adults with Type 2 Diabetes Mellitus 2016 · 150 mg resveratrol · Adults aged 40–80 years with type 2 diabetes mellitus | 150 mg | 1 day | 36 |
| Resveratrol has a positive effect on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary heart disease 2017 · research group · Patients with stable coronary heart disease and class II stable angina pectoris; age and sex not reported | 100 mg | 60 days | 30 |
| Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial 2020 · resveratrol plus risperidone · Adults aged 18–60 with chronic stable schizophrenia, disease duration of at least 2 years, and a PANSS negative subscale score of at least 15 | 200 mg | 8 weeks | 30 |
| Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults 2013 · trans-resveratrol · Obese but otherwise healthy adults; age range and sex not reported | 75 mg | 6 weeks | 28 |
| Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults 2014 · resveratrol · Healthy overweight older adults aged 50–75 years | 200 mg | 26 weeks | 23 |
| Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans 2011 · resVida™ (resveratrol) condition · Obese, otherwise healthy men; age range not reported; no family history of diabetes or other endocrine disorder | 150 mg | 30 days | 11 |
| A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea) 2021 · lower-dose resveratrol · Male veterans aged 46–57 with Gulf War Illness | 200 mg | 30 days | 9 |
| Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease 2012 · RES group · Caucasian patients after myocardial infarction with coronary artery disease; age and sex not specified | 10 mg | 90 days | — |
| Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial 2017 · resveratrol group · Post-menopausal women aged 45–85 years without the specified excluded conditions | 150 mg | 14 weeks | — |
| Resveratrol supplementation reduces pain experience by postmenopausal women 2017 · trans-resveratrol · Healthy postmenopausal women | 150 mg | 14 weeks | — |
| Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial 2020 · resveratrol supplementation · healthy postmenopausal women | 150 mg | 1 year | — |
| The impact of resveratrol on the outcome of the in vitro fertilization: an exploratory randomized placebo-controlled trial 2024 · Study Group · Women aged 35 years or older with infertility, normal ovarian reserve markers, and undergoing IVF | 150 mg | 90 days | 40 |
| Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial 2024 · NR + resveratrol · Adults with peripheral artery disease; mean age 70.73 years in this arm; men and women | 125 mg | 26 weeks | 33 |
| Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance 2017 · Group B · Adults with chronic hepatitis C receiving pegylated interferon-α-2b and ribavirin | 59.4 mg | 1 year | 30 |
| Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation 2021 · tRES-HESP · Overweight and obese adults with impaired metabolic health; 9 participants met criteria for prediabetes | 90 mg | 8 weeks | 29 |
| Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects 2014 · E+R · Healthy overweight women and men, mean age 35 years | 200 mg | 3 days | 18 |
| Short-term supplementation with a specific combination of dietary polyphenols increases energy expenditure and alters substrate metabolism in overweight subjects 2014 · E+R+S · Healthy overweight women and men, mean age 35 years | 200 mg | 3 days | 18 |
| Efficacy of a Mouthwash Containing Resveratrol in Reducing Halitosis-related P. gingivalis: A Randomized Triple-blind Trial 2025 · RSV group · Male and female undergraduate dental students aged 20–23 with halitosis due to gingivitis | 30 mL | 7 days | 17 |
| The effects of polyphenol supplementation on adipose tissue morphology and gene expression in overweight and obese humans 2018 · EGCG+RES · Overweight and obese men and premenopausal women; ages not specified | 80 mg | 12 weeks | 11 |
| Influence of exercise training with resveratrol supplementation on skeletal muscle mitochondrial capacity 2016 · resveratrol plus piperine · healthy young adults | 500 mg | 4 weeks | — |
| Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study 2017 · equol and resveratrol group · Healthy recently menopausal women aged 50–55 years with hot flashes, anxiety and depressive symptoms | 25 mg | 12 weeks | — |
| Effects of resveratrol on bone health in type 2 diabetic patients. A double-blind randomized-controlled trial 2018 · Resv40 arm · Adults aged 40 years or older with diagnosed type 2 diabetes; median age 66 years, predominantly men, all women postmenopausal | 40 mg | 26 weeks | 65 |
| Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo-Controlled Trial 2020 · Resveratrol · Women aged 45–85 years who were postmenopausal for more than 12 months and not taking hormone replacement therapy; community-dwelling, with a range of bone-health status including normal bone density, osteopenia, and osteoporosis. | 150 mg | 1 year | 63 |
| Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial 2023 · Combo group (CG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7 | 50 mg | 30 days | 44 |
| Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial 2023 · Supplement group (SG) · Adults aged 18–45 with acute sciatica due to lumbar disc herniation and low-back pain NRS 5–7 | 50 mg | 30 days | 41 |
| Effects of 12 Weeks of Essential Amino Acids (EAA)-Based Multi-Ingredient Nutritional Supplementation on Muscle Mass, Muscle Strength, Muscle Power and Fatigue in Healthy Elderly Subjects: A Randomized Controlled Double-Blind Study 2019 · multi-ingredient nutritional supplement (SUPP) · Healthy men and women aged 65–80 years, not selected for a diagnosed disease; the group was described as non-sarcopenic and well-nourished | 100 mg | 12 weeks | 19 |
| Supportive treatment of vascular dysfunction in pediatric subjects with obesity: the OBELIX study 2022 · Treatment group · Children aged 6–17 years with obesity (BMI above the 95th percentile for age) | 20 mg | 26 weeks | 16 |
| Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass 2022 · supplement (SUPP) · Community-dwelling older adults with low skeletal muscle mass; mean age 74.9 years; 18 men and 19 women in the study overall | 150 mg | 26 weeks | — |
| Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease 2017 · resveratrol · Adults with mild-to-moderate dementia due to Alzheimer’s disease; older individuals; sex and age range not specified | 500 mg | 52 weeks | 56 |
| Resveratrol Attenuates CSF Markers of Neurodegeneration and Neuroinflammation in Individuals with Alzheimer's Disease 2025 · resveratrol · Individuals with mild-to-moderate dementia due to Alzheimer’s disease | 500 mg | 52 weeks | 56 |
| Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial 2013 · resveratrol phase · healthy adult smokers | 500 mg | 30 days | 50 |
| Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 2018 · Resv500 arm · Adults aged 40 years or older with type 2 diabetes, BMI below 35 kg/m², treated with diet and/or non-insulin hypoglycemic agents | 500 mg | 26 weeks | 43 |
| Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes 2023 · experimental group 500 mg/day (EG500) · Men and women aged 60–74 with type 2 diabetes treated with metformin and/or glibenclamide | 500 mg | 26 weeks | 43 |
| Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial 2019 · resveratrol · Patients with type 2 diabetes and albuminuria | 500 mg | 90 days | 30 |
| The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease 2019 · resveratrol group · Patients with type 2 diabetes mellitus and coronary heart disease; age and sex not specified | 500 mg | 4 weeks | 28 |
| Gene Expression of Sirtuin-1 and Endogenous Secretory Receptor for Advanced Glycation End Products in Healthy and Slightly Overweight Subjects after Caloric Restriction and Resveratrol Administration 2018 · RSV group · Adults aged 55–65, healthy and slightly overweight; 12 men and 12 postmenopausal women | 500 mg | 30 days | 24 |
| Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial 2021 · resveratrol (RSV) group · Men and postmenopausal women aged 50–65 years who were healthy and slightly overweight, without the listed cardiometabolic conditions | 500 mg | 30 days | 24 |
| The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women-A Pilot Randomized Clinical Trial 2024 · Group A (resveratrol and vitamin C placebo) · Women aged 50–60 with early postmenopause and insulin resistance | 500 mg | 90 days | 13 |
| Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: A randomized trial 2017 · resveratrol administration · Healthy adults aged 55–65 years, women and men | 500 mg | 30 days | — |
| Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 2017 · Resv 500 arm · Patients with type 2 diabetes mellitus; age range and sex not specified | 500 mg | 26 weeks | — |
| Resveratrol Enhances Exercise-Induced Cellular and Functional Adaptations of Skeletal Muscle in Older Men and Women 2017 · resveratrol (RSV) · Men and women aged 65–80 years | 500 mg | 12 weeks | — |
| Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial 2025 · resveratrol group · People with relapsing-remitting multiple sclerosis; age and sex not specified | 500 mg | 8 weeks | — |
| Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial 2023 · equol/resveratrol combination · Caucasian postmenopausal women aged 50–55 with menopausal complaints and BMI 20 to <25 kg/m² | 25 mg | 1 year | 38 |
| Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial 2012 · resveratrol-enriched grape extract (GE-RES, Stilvid®) · Statin-treated patients in primary prevention of cardiovascular disease | 8 mg | 26 weeks | — |
| A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia 2023 · 300 mg/d resveratrol · Adults aged 35–70 with dyslipidemia | 300 mg | 8 weeks | 43 |
| Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial 2023 · RES group · Patients with hypertension; age and sex not specified | 400 mg | 26 weeks | 43 |
| A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia 2023 · 600 mg/d resveratrol · Adults aged 35–70 with dyslipidemia | 600 mg | 8 weeks | 41 |
| Effect of Resveratrol on Markers of Oxidative Stress and Sirtuin 1 in Elderly Adults with Type 2 Diabetes 2023 · experimental group 1000 mg/day (EG1000) · Men and women aged 60–74 with type 2 diabetes treated with metformin and/or glibenclamide | 1 g | 26 weeks | 40 |
| Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial 2019 · resveratrol group · Patients with PCOS who were candidates for ICSI; age and sex range not stated | 800 mg | 40 days | 31 |
| Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial 2024 · resveratrol group · Women aged 18–35 with PCOS undergoing ICSI treatment | 800 mg | 60 days | 28 |
| Effects of resveratrol on inflammatory cytokines in COVID-19 patients: a randomized, double-blinded, placebo-controlled clinical trial 2025 · resveratrol · Patients with COVID-19; age and sex not specified | 750 mg | 10 days | 24 |
| Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation 2014 · trans-resveratrol · Adults described as healthy and young; age range and sex not specified | 250 mg | 1 day | 23 |
| The Administration of Resveratrol and Vitamin C Reduces Oxidative Stress in Postmenopausal Women-A Pilot Randomized Clinical Trial 2024 · Group B (resveratrol and vitamin C) · Women aged 50–60 with early postmenopause and insulin resistance | 500 mg | 90 days | 15 |
| Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study 2014 · moderate dose resveratrol condition · Overweight men and women aged 65 years and older | 300 mg | 90 days | 12 |
| Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study 2014 · high dose resveratrol condition · Overweight men and women aged 65 years and older | 1 g | 90 days | 10 |
| Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers 2009 · trans-resveratrol 50 mg group · healthy adult men and women | 300 mg | — | 8 |
| Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers 2009 · trans-resveratrol 100 mg group · healthy adult men and women | 600 mg | — | 8 |
| Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers 2009 · trans-resveratrol 150 mg group · healthy adult men and women | 900 mg | — | 8 |
| The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans 2017 · resveratrol group · healthy Japanese adults, males and females, median age 36 years (range 30–50) | 1 g | 4 weeks | 5 |
| Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus 2012 · intervention group · Patients with type 2 diabetes mellitus; age and sex not reported | 250 mg | 90 days | — |
| Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men 2015 · 1,000 mg resveratrol group · Middle-aged men with metabolic syndrome | 1 g | 120 days | — |
| The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis 2017 · intervention group · Patients with type 2 diabetes and chronic periodontitis; age and sex not reported | 480 mg | 4 weeks | — |
| The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial 2018 · resveratrol group · Adults with type 2 diabetes; age and sex not reported | 800 mg | 8 weeks | — |
| Resveratrol supplementation decreases blood glucose without changing the circulating CD14(+)CD16(+) monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study 2018 · resveratrol group · Patients with type 2 diabetes; age and sex not stated | 800 mg | 8 weeks | — |
| The Effect of Resveratrol Supplementation on Cardio-Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double-Blind Controlled Trial 2019 · trans-resveratrol group · Overweight patients with type 2 diabetes mellitus, BMI 25–30; age and sex not specified | 1 g | 8 weeks | — |
| Resveratrol treatment in patients with polycystic ovary syndrome decreased pro-inflammatory and endoplasmic reticulum stress markers 2020 · resveratrol treatment group · Patients with polycystic ovary syndrome (PCOS); age and sex details not stated | 800 mg | 40 days | — |
| The effect of resveratrol supplementation on serum levels of asymmetric de-methyl-arginine and paraoxonase 1 activity in patients with type 2 diabetes: A randomized, double-blind controlled trial 2020 · resveratrol · Patients with type 2 diabetes; age and sex range not reported | 1 g | 8 weeks | — |
| Oral resveratrol supplementation improves Metabolic Syndrome features in obese patients submitted to a lifestyle-changing program 2020 · Resveratrol · Adults aged 30–60 years with BMI ≥30 kg/m² and metabolic syndrome features | 250 mg | 90 days | — |
| The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial 2021 · trans-resveratrol · Patients with type 2 diabetes mellitus; age range and sex not stated | 1 g | 8 weeks | — |
| Beneficial Role of Resveratrol on Oxidative Stress in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial 2025 · resveratrol · Women with polycystic ovary syndrome (age range not reported) | 800 mg | 60 days | — |
| Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics 2011 · SRT501 group · Adults aged 18 years or older with stage IV colorectal cancer and hepatic metastases, awaiting resection of liver metastases | 5 g | 2 weeks | 6 |
| Role of resveratrol supplementation in regulation of glucose hemostasis, inflammation and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial 2022 · resveratrol · Patients with type 2 diabetes mellitus taking oral hypoglycemic drugs; age and sex not specified | 200 mg | 24 weeks | 55 |
| Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation 2018 · Resv40 arm · Adults aged 40 years or older with type 2 diabetes, BMI below 35 kg/m², treated with diet and/or non-insulin hypoglycemic agents | 40 mg | 26 weeks | 43 |
| A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia 2023 · 100 mg/d resveratrol · Adults aged 35–70 with dyslipidemia | 100 mg | 8 weeks | 41 |
| Role of δ-tocotrienol and resveratrol supplementation in the regulation of micro RNAs in patients with metabolic syndrome: A randomized controlled trial 2023 · TRM group · Adults with metabolic syndrome; age range and sex not specified | 300 mg | 24 weeks | 41 |
| Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial 2019 · resveratrol · Men and non-pregnant women aged 20–65 with a new diagnosis of dyslipidemia | 100 mg | 60 days | 35 |
| Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol 2020 · resveratrol group · Adults with heart failure with reduced ejection fraction, NYHA class II or III; mean age 66.7 years; 17 women and 43 men across both trial arms | 100 mg | 90 days | 30 |
| Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease 2013 · GE-RES, resveratrol-containing grape extract group (group C) · Adults aged 60 on average, men and women with stable coronary artery disease | 8.1 mg | 1 year | 25 |
| Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer 2012 · P. cuspidatum with 5 mg trans-resveratrol (low-dose resveratrol) · Women at increased breast cancer risk; age range not stated | 10 mg | 12 weeks | 13 |
| Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer 2012 · P. cuspidatum with 50 mg trans-resveratrol (high-dose resveratrol) · Women at increased breast cancer risk; age range not stated | 100 mg | 12 weeks | 13 |
| Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes 2018 · resveratrol condition · Overweight males at increased risk of type 2 diabetes, with at least one first-degree relative with type 2 diabetes, BMI 27–35, and disrupted glucose homeostasis | 150 mg | 34 days | 13 |
| Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion 2014 · trans-resveratrol group · Patients with metabolic syndrome diagnosed according to International Diabetes Federation criteria; age and sex not reported | 1.5 g | 90 days | 12 |
| The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men 2014 · resveratrol · 11 healthy obese men | 150 mg | 30 days | 11 |
| Resveratrol supplementation reduces ACE2 expression in human adipose tissue 2021 · Resveratrol · Otherwise healthy males with obesity | 150 mg | 30 days | 11 |
| Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects 2013 · resveratrol · Obese men, mean age 52 ± 2 years | 150 mg | 30 days | 10 |
| Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers 2009 · trans-resveratrol 25 mg group · healthy adult men and women | 150 mg | — | 8 |
| Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients 2011 · resveratrol group · patients with type 2 diabetes; age and sex not stated | 10 mg | 4 weeks | — |
| One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease 2012 · resveratrol-rich grape supplement · Patients at high cardiovascular-disease risk undergoing primary prevention, including people with diabetes or hypercholesterolemia plus at least one other cardiovascular risk factor; age and sex not reported | 8 mg | 1 year | — |
| Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects 2012 · RES · Adults with obesity (BMI 30–40); sex and age range not reported | 0.66 mmol | 4 weeks | — |
| Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects 2012 · RTP · Adults with obesity (BMI 30–40); sex and age range not reported | 0.66 mmol | 4 weeks | — |
| Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure 2014 · resveratrol group · Adults with type 2 diabetes mellitus; age and sex not reported | 3 g | 12 weeks | — |
| Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial 2014 · RSV(low) · Middle-aged obese men with metabolic syndrome; mean age 49.3 years | 150 mg | 16 weeks | — |
| Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men 2015 · 150 mg resveratrol group · Middle-aged men with metabolic syndrome | 150 mg | 120 days | — |
| Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial 2016 · Resveratrol · Women of reproductive age with polycystic ovary syndrome (PCOS) | 1.5 g | 90 days | — |
| Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial 2017 · Resv 40 arm · Patients with type 2 diabetes mellitus; age range and sex not specified | 40 mg | 26 weeks | — |
| Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus 2017 · resveratrol group · patients with type 2 diabetes mellitus; age and sex not specified | 28 mg | 12 weeks | — |
| The Oral Bioavailability of Trans-Resveratrol from a Grapevine-Shoot Extract in Healthy Humans is Significantly Increased by Micellar Solubilization 2018 · Native powder · Healthy adult volunteers; six women and six men | 30 mg | 1 day | 12 |
| The Oral Bioavailability of Trans-Resveratrol from a Grapevine-Shoot Extract in Healthy Humans is Significantly Increased by Micellar Solubilization 2018 · Liquid micelles · Healthy adult volunteers; six women and six men | 30 mg | 1 day | 12 |
| Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial 2023 · arm-2 · Women aged 20–35 years with obesity and oligo-anovulatory PCOS | 2 g | 12 weeks | 55 |
| Resveratrol in Patients with Minimal Hepatic Encephalopathy 2018 · Group A (resveratrol) · Adults aged 25–65 with cirrhosis and minimal hepatic encephalopathy | 19.8 mg | 90 days | 35 |
| Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation 2014 · trans-resveratrol with piperine · Adults described as healthy and young; age range and sex not specified | 250 mg | 1 day | 23 |
| Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity 2024 · EGCG+RES · Healthy men and women aged 20–50 years with overweight or obesity and normal glucose tolerance | 80 mg | 12 weeks | 20 |
| An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol 2010 · PCE group · Normal-weight healthy subjects; age and sex not reported | 40 mg | 6 weeks | 10 |
| Combined epigallocatechin-3-gallate and resveratrol supplementation for 12 wk increases mitochondrial capacity and fat oxidation, but not insulin sensitivity, in obese humans: a randomized controlled trial 2016 · EGCG+RES · Overweight and obese adults; 18 men among 38 participants, mean age 38 ± 2 years; insulin resistance is discussed, but is not specified as an inclusion criterion | 80 mg | 12 weeks | — |
| Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women 2017 · EGCG+RES · Overweight and obese men and women; mean age 37.8 years; 18 men and 19 women enrolled | 80 mg | 12 weeks | — |
| Global testing of shifts in metabolic phenotype 2018 · PP intervention · Overweight and obese adults | 80 mg | 12 weeks | — |
| Modulation of Energy Sensing by Leucine Synergy with Natural Sirtuin Activators: Effects on Health Span 2020 · leucine-resveratrol · Prediabetic subjects; age and sex not stated | 50 mg | 4 weeks | — |
| Polyphenol-Related Gut Metabotype Signatures Linked to Quality of Life in Postmenopausal Women: A Randomized, Placebo-Controlled Crossover Trial 2025 · Polyphenol-rich supplement (PPs) · Healthy postmenopausal women aged 45–59 with at least one climacteric symptom | 150 mg | 8 weeks | 78 |